David Mesher
About
David Mesher is a scholar working on Epidemiology, Surgery and Oncology.
According to data from OpenAlex, David Mesher has authored 52 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Epidemiology, 28 papers in Surgery and 11 papers in Oncology. Recurrent topics in David Mesher's work include Cervical Cancer and HPV Research (33 papers), Genital Health and Disease (25 papers) and Reproductive tract infections research (11 papers). David Mesher is often cited by papers focused on Cervical Cancer and HPV Research (33 papers), Genital Health and Disease (25 papers) and Reproductive tract infections research (11 papers). David Mesher collaborates with scholars based in United Kingdom, United States and Italy. David Mesher's co-authors include Peter Sasieni, Jack Cuzick, Kate Soldan, D M Parkin, Daniel M. Berney, Alexander Gutin, Henrik Møller, Anne Szarewski, Peter T. Scardino and Adib Younus and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
David Mesher
50 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David Mesher United Kingdom | 26 | 1.4k | 940 | 769 | 613 | 527 | 52 | 3.2k | ||
| André‐Pascal Sappino Switzerland | 24 | 622 0.4× | 436 0.5× | 235 0.3× | 822 1.3× | 515 1.0× | 40 | 2.9k | ||
| Kevin M. Elias United States | 30 | 460 0.3× | 1.0k 1.1× | 252 0.3× | 761 1.2× | 805 1.5× | 152 | 4.6k | ||
| Rodrigue Mortel United States | 38 | 1.3k 1.0× | 939 1.0× | 348 0.5× | 1.1k 1.8× | 526 1.0× | 122 | 4.6k | ||
| Mary R. Schwartz United States | 30 | 1.3k 0.9× | 1.1k 1.1× | 446 0.6× | 1.1k 1.8× | 579 1.1× | 128 | 3.5k | ||
| Robbert G. M. Bredius Netherlands | 37 | 950 0.7× | 176 0.2× | 293 0.4× | 698 1.1× | 721 1.4× | 128 | 4.3k | ||
| Leo B. Twiggs United States | 38 | 1.4k 1.0× | 1.0k 1.1× | 342 0.4× | 1.1k 1.8× | 697 1.3× | 134 | 4.5k | ||
| Giora M. Mavligit United States | 37 | 481 0.3× | 643 0.7× | 834 1.1× | 1.9k 3.1× | 833 1.6× | 153 | 4.3k | ||
| Kousaku Matsubara Japan | 26 | 485 0.4× | 292 0.3× | 301 0.4× | 161 0.3× | 386 0.7× | 108 | 2.0k | ||
| Michel H. Maillard Switzerland | 19 | 489 0.4× | 290 0.3× | 403 0.5× | 1.4k 2.3× | 649 1.2× | 55 | 3.0k | ||
| Sophie Derchain Brazil | 31 | 1.3k 1.0× | 830 0.9× | 180 0.2× | 957 1.6× | 744 1.4× | 218 | 3.5k |
Countries citing papers authored by David Mesher
Since
Specialization
Citations
This map shows the geographic impact of David Mesher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Mesher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Mesher more than expected).
Fields of papers citing papers by David Mesher
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Mesher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Mesher. The network helps show where David Mesher may publish in the future.
Co-authorship network of co-authors of David Mesher
This figure shows the co-authorship network connecting the top 25 collaborators of David Mesher. A scholar is included among the top collaborators of David Mesher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Mesher. David Mesher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Padget, Michael, Inês Campos-Matos, Alberto Mateo‐Urdiales, et al.. (2023). A comparison of COVID-19 incidence rates across six European countries in 2021. Eurosurveillance. 28(40).
2.
Rebolj, Matejka, Francesca Pesola, Christopher Mathews, et al.. (2022). The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. British Journal of Cancer. 127(2). 278–287.
3.
Mesher, David, Sara L. Thomas, Ezra Linley, et al.. (2021). Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England. Vaccine. 39(30). 4210–4218.
4.
Nugent, Diarmuid, Oliver Stirrup, Sarah Pett, et al.. (2020). Performance of human papillomavirus DNA detection in residual specimens taken forChlamydia trachomatisandNeisseria gonorrhoeaenucleic acid amplification testing in men who have sex with men. Sexually Transmitted Infections. 97(7). 541–546.
5.
King, Eleanor M., David Mesher, Pam Sonnenberg, et al.. (2020). HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sexually Transmitted Infections. 97(5). 382–386.
6.
Mesher, David, et al.. (2017). Attendance of MSM at Genitourinary Medicine services in England: implications for selective HPV vaccination programme (a short communication). Sexually Transmitted Infections. 94(7). 542–544.
7.
Tanton, Clare, David Mesher, Simon Beddows, et al.. (2017). Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Research. 3. 36–41.
8.
Mesher, David, Kavita Panwar, Sara L. Thomas, Simon Beddows, & Kate Soldan. (2016). Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 6(2). e009915–e009915.
9.
Mesher, David, Kate Cuschieri, Sam Hibbitts, et al.. (2014). Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. Journal of Clinical Pathology. 68(2). 135–140.
10.
Lim, Anita WW, David Mesher, & Peter Sasieni. (2014). Estimating the workload associated with symptoms-based ovarian cancer screening in primary care: an audit of electronic medical records. BMC Family Practice. 15(1). 200–200.
11.
Mesher, David, Kate Soldan, Rebecca Howell‐Jones, et al.. (2013). Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 32(1). 26–32.
12.
Cuzick, Jack, Louise Cadman, David Mesher, et al.. (2013). Comparing the performance of six human papillomavirus tests in a screening population. British Journal of Cancer. 108(4). 908–913.
13.
Harwood, Catherine, David Mesher, J.M. McGregor, et al.. (2012). A Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in an Ethnically Diverse Population. American Journal of Transplantation. 13(1). 119–129.
14.
Lim, Anita WW, David Mesher, Aleksandra Gentry‐Maharaj, et al.. (2012). Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. JNCI Journal of the National Cancer Institute. 104(2). 114–124.
15.
Heard, Isabelle, et al.. (2012). Characteristics of HPV infection over time in European women who are HIV‐1 positive. BJOG An International Journal of Obstetrics & Gynaecology. 120(1). 41–49.
16.
Mesher, David, et al.. (2011). Assessing Peanut Consumption in a Population of Mothers and Their Children in the UK. SHILAP Revista de lepidopterología. 4(2). 38–44.
17.
Cuzick, Jack, Gregory P. Swanson, Gabrielle Fisher, et al.. (2011). Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. The Lancet Oncology. 12(3). 245–255.
18.
Singh, Shalini, et al.. (2011). Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Research and Treatment. 132(2). 625–629.
19.
Szarewski, Anne, Louise Cadman, David Mesher, et al.. (2011). HPV self-sampling as an alternative strategy in non-attenders for cervical screening – a randomised controlled trial. British Journal of Cancer. 104(6). 915–920.
20.
Mesher, David, Anne Szarewski, Louise Cadman, et al.. (2010). Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. British Journal of Cancer. 102(9). 1405–1410.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by André‐Pascal Sappino Breakdown of academic impact, for papers by Kevin M. Elias Breakdown of academic impact, for papers by Rodrigue Mortel Breakdown of academic impact, for papers by Mary R. Schwartz Breakdown of academic impact, for papers by Robbert G. M. Bredius Breakdown of academic impact, for papers by Leo B. Twiggs Breakdown of academic impact, for papers by Giora M. Mavligit Breakdown of academic impact, for papers by Kousaku Matsubara Breakdown of academic impact, for papers by Michel H. Maillard Breakdown of academic impact, for papers by Sophie Derchain